Ultragenyx Reports Positive Phase 2 Study Data By: Benzinga via Benzinga September 19, 2016 at 11:16 AM EDT Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) revealed positive interim data from the second-stage study of KRN23 for tumor-induced ... Read More >> Related Stocks: Ultragenyx Pharmaceu